Discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Ball, S.G.
Lancet 355(9214): 1558
2000
ISSN/ISBN: 0140-6736 PMID: 10801204 Document Number: 518085
Document emailed within 1 workday
Related Documents
Agabiti-Rosei, E.; Muiesan, M.L.; Rizzoni, D.; Zulli, R.; Calebich, S.; Beschi, M.; Castellano, M.; Muiesan, G. 1992: Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin Journal of Human Hypertension 6(1): 9-15Mamedov, M.N.; Perova, N.V.; Kosmatova, O.V.; Khadipash, L.A.; Kiseleva, N.V.; Oganov, R.G. 2003: Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome Kardiologiia 43(3): 13-19
Auer, J.; Berent, R.; Weber, T.; Porodko, M.; Mayr, H.; Maurer, E.; Eber, B. 2001: Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents Wiener Medizinische Wochenschrift 151(1-2): 13-17
Ahaneku, J.E.; Taylor, G.O.; Agbedana, E.O.; Walker, O.; Salako, L.A. 1994: Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients Jpma. Journal of the Pakistan Medical Association 44(7): 166-169
Pearson, T.A.; Laurora, I.; Chu, H.; Kafonek, S. 2000: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Archives of Internal Medicine 160(4): 459-467
Bubnova, M.G. 2004: Atorvastatin: lipid lowering activity, pleiotropic properties and efficacy in prevention of atherosclerosis and coronary heart disease Kardiologiia 44(8): 96-104
Widimský, Jří. 2015: PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension Vnitrni Lekarstvi 61(12): 1067-1071
Tziomalos, K. 2016: Unresolved issues in lipid-lowering treatment Panminerva Medica 58(2): 191-195
Serkova, V.K.; Burdeĭnaia, L.V. 2002: Effect of antihypertensive therapy on indices for lipid peroxidation and antioxidant system in patients with hypertensive heart Likars'ka Sprava 2002(5-6): 12-16
Paragh, G.; Balogh, Z.; Boda, J.; Mohácsi, A.; Kovács, P.; Polgár, P.; Wórum, F.; Kakuk, G. 1997: Lipid lowering treatment in secondary prevention following myocardial infarct Orvosi Hetilap 138(29): 1849-1853
Sukonthasarn, A.; Homsanit, M.; Prommete, B.; Chotinaiwattarakul, C.; Piamsomboon, C.; Likittanasombat, K. 2011: Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey Journal of the Medical Association of Thailand 94(12): 1424-1434
Kuemmerle, H.P. 1981: Lipid-lowering agents and their meaning in the treatment of the fat metabolism-atherosclerosis functional circle International Journal of Clinical Pharmacology Therapy and Toxicology 19(7): 289-296
Zhdan, V.; Khaymenova, G.; Shilkina, L.; Martynyuk, D.; Babanina, M.; Mamontova, T. 2017: Determine the effectiveness of lipid-lowering therapy in patients with chronic obstructive pulmonary disease combined with coronary heart disease Wiadomosci Lekarskie 70(2 Part 2): 303-305
Tharavanij, T.; Wongtanakarn, S.; Lerdvuthisopon, N.; Teeraaunkul, S.; Youngsriphithak, P.; Sritipsukho, P. 2010: Lipid lowering efficacy between morning and evening simvastatin treatment: a randomized double-blind study Journal of the Medical Association of Thailand 93(Suppl 7): S109-S113
1974: Round table discussion about lipids in ischemic heart diseases: the importance of diagnosing and observing high risk families. The value of lowering high blood lipid levels Nordisk Medicin 89(9): 281-288
Goldberg, R.J.; Gore, J.M.; Alpert, J.S.; Dalen, J.E. 1986: Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study JAMA 255(20): 2774-2779
Gratzke, P.; Kirby, R.S. 2000: Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily MMW Fortschritte der Medizin 142(26-27): 40
Jiménez-García, R.; Anegón, M.; Esteban, J.; Carrasco, P.; Apaolaza, I.; Gil, A. 2003: Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients International Journal of Clinical Practice 57(4): 267-272
Gratzke, P.; Kirby, R.S. 2000: Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability Fortschritte der Medizin. Originalien 118(Suppl 2): 83-92
Fujii, S.; Kaku, K.; Andou, S.; Nakayama, H.; Suetsugu, N.; Inoue, M.; Yoshizaki, Y.; Matsuda, M.; Tanaka, M.; Okafuji, S. 1993: Glucose and lipid metabolism during long-term antihypertensive treatment with indapamide in non-insulin-dependent diabetic patients Clinical Therapeutics 15(6): 1041-1050